Important update (2019): please note that this document was published on 29 January 2016 and considered the Tempo 3:4 Trial and former EMA licence regarding Tolvaptan. Since then, the Tempo 4:4 results have been published, there has been a new trial (REPRISE) and an update of the EMA licence, which means that this ERBP document is outdated. ERBP cannot confirm at this time whether an update will follow.
ERA Operative Headquarters
Strada dei Mercati 16/A
I-43126 Parma – Italy
Phone: +39 0521 989078
ERA Registered Office
c/o PKF Littlejohn, 15 Westferry Circus, Canary Wharf
London E14 4HD – United Kingdom